Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized dose-titration study of ISIS 494372 in patients with high lipoprotein(a)
2014-000701-13Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jun 2014
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lipoprotein(a) hyperlipoproteinemia (Lp(a)) comparing ISIS 494372 escalating dose arm with Placebo arm (2 arms). Primary endpoint: Primary safety and tolerability endpoint. Started Jun 2014; status: completed.
02
Drugs
ISIS-APO(a)Rx
03
Conditions
lipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on 2014-000701-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000701-13.